From the Editor-in-Chief

Patients in this age group have particular needs, and cancer centers are beginning to tailor programs for them.

by William G. Nelson, MD, PhD

Forward Look

Despite efforts by policymakers, a gender gap persists in clinical trial participation.

by Lindsey Konkel

Forward Look

Several targeted drugs were approved in 2020 to treat the most common type of lung cancer.

by Ashley P. Taylor

Forward Look

Treatments capable of crossing the blood-brain barrier provide new options for patients whose cancer has spread to the brain.

by Bradley Jones

In recent months, drugmakers have announced they are withdrawing indications for four immune checkpoint inhibitors in consultation with the Food and Drug Administration. What does this mean for patients who are taking these drugs?

by Anna Goshua

African Americans are underrepresented in the Be The Match bone marrow donor registry. Patient advocates are working to change that.

by Jon Kelvey

Nonprofits provide support to young cancer patients in need of fertility preservation, and a childhood cancer survivor joins the first all-civilian mission to space.

by Bradley Jones

Scientists and physicians discussed advances in targeted therapies and immunotherapies, as well as the lessons COVID-19 research has taught to cancer researchers.

by Kevin McLaughlin

Two immune checkpoint inhibitors are now approved for treatment of some people with advanced breast cancer, but trial results have raised some questions.

by Anna Goshua

Stool-based tests could increase access to colorectal cancer screening.

by Jen Tota McGivney